Even though latency II is defined for EBV-positive NPC, LMP1 expression is detected in about 70% of all cases.[2] Latency II was also originally proposed for gastric carcinoma [39], [40] but recently, the lack of detection of LMP1 in this malignancy better defined EBV latency pattern as latency I.[2], [41], [42] It is important to define EBV protein expression and latency profile in this disease in order to identify viral proteins which interact with cellular factors and deregulate signaling pathways which could at last trigger neoplastic processes. Here, PDLIM7 is linked to gastric carcinoma.